Roche has inked a new deal with Dyno Ther­a­peu­tics to de­vel­op next-gen­er­a­tion AAV cap­sids for gene ther­a­pies tar­get­ing neu­ro­log­i­cal dis­eases, ex­pand­ing the ...

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. In a new deal potentially worth more than $1 billion, Roche is paying Dyno $50 million upfront to ...

Roche will apply Dyno Therapeutics’ engineered adeno-associated virus (AAV) capsid platform to develop next-generation AAV vectors for gene therapies targeting unspecified neurological diseases ...

New strategic partnership leverages the power of the Dyno platform, enabling Roche to advance next-generation AAV gene therapies across multiple targets Dyno to receive US$50 million upfront cash ...

With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy delivery technology, which synthesizes virus capsids with better functionality ...

Explosives and blasting company Dyno Nobel has been going for 180 years, but it now has its sights set on the future of the sector. Braden Lusk, chief technology and marketing officer at the company, ...